Resultados de procura - Vincent A. Miller

Limitar resultados
  1. 1
    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

    High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer por Jennifer Clarke, William Pao, Nian Wu, Vincent A. Miller, Andrew B. Lassman

    Publicado 2010
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer

    New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer por Geoffrey R. Oxnard, Maria E. Arcila, Juliann Chmielecki, Marc Ladanyi, Vincent A. Miller, William Pao

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  3. 3
    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design

    Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with <i>EGFR</i>-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Cl... por Jamie E. Chaft, Geoffrey R. Oxnard, Camelia S. Sima, Mark G. Kris, Vincent A. Miller, Gregory J. Riely

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  4. 4
    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma

    Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma por James Bean, Gregory J. Riely, Marissa N. Balak, Jenifer L. Marks, Marc Ladanyi, Vincent A. Miller, William Pao

    Publicado 2008
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  5. 5
    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling

    Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling por Angel Qin, Adrienne Johnson, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Alexa B. Schrock, Shirish M. Gadgeel

    Publicado 2018
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  6. 6
    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping

    Screening for Germline EGFR T790M Mutations Through Lung Cancer Genotyping por Geoffrey R. Oxnard, Vincent A. Miller, Mark E. Robson, Christopher G. Azzoli, William Pao, Marc Ladanyi, Maria E. Arcila

    Publicado 2012
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  7. 7
    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden

    Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden por Victoria E. Wang, Anatoly Urisman, Lee A. Albacker, Siraj M. Ali, Vincent A. Miller, Rahul Aggarwal, David M. Jablons

    Publicado 2017
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  8. 8
    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities

    Phosphatidylinositol 3‐kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities por Sherri Z. Millis, Denis L. Jardim, Lee A. Albacker, Jeffrey S. Ross, Vincent A. Miller, Siraj M. Ali, Razelle Kurzrock

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  9. 9
    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

    Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain por William Pao, Vincent A. Miller, Katerina Politi, Gregory J. Riely, Romel Somwar, Maureen F. Zakowski, Mark G. Kris, Harold Varmus

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  10. 10
    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations

    Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> Mutations por Paul K. Paik, Maria E. Arcila, Michael Fara, Camelia S. Sima, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Gregory J. Riely

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  11. 11
    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study

    Real-World Evidence In Support Of Precision Medicine: Clinico-Genomic Cancer Data As A Case Study por Vineeta Agarwala, Sean Khozin, Gaurav Singal, Claire O’Connell, Deborah Kuk, Gerald Li, Anala Gossai, Vincent A. Miller, Amy P. Abernethy

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Revisão
    Engadir a favoritos
    Gardado en:
  12. 12
    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors

    Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors por Darren Sigal, Munveer S. Bhangoo, Jonathan A. Hermel, Dean C. Pavlick, Garrett M. Frampton, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali

    Publicado 2018
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  13. 13
    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation

    Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation por Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller

    Publicado 2010
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  14. 14
    EGFR Mutations in Lung Adenocarcinomas

    EGFR Mutations in Lung Adenocarcinomas por Allan R. Li, Dhananjay Chitale, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski, Valerie W. Rusch, Mark G. Kris, Marc Ladanyi

    Publicado 2008
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  15. 15
    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib

    Phase II Trial of Dasatinib for Patients with Acquired Resistance to Treatment with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Erlotinib or Gefitinib por Melissa L. Johnson, Greg J. Riely, Naiyer A. Rizvi, Christopher G. Azzoli, Mark G. Kris, Camelia S. Sima, Michelle S. Ginsberg, William Pao, Vincent A. Miller

    Publicado 2011
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  16. 16
    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

    Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers por Aaron M. Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip Pravin Patel, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  17. 17
    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies

    Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies por Aaron M. Goodman, Shumei Kato, Philip R. Cohen, Amélie Boichard, Garrett M. Frampton, Vincent A. Miller, Philip J. Stephens, Gregory A. Daniels, Razelle Kurzrock

    Publicado 2017
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  18. 18
    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer

    Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer por Vincent A. Miller, James R. Rigas, Prudence A. Francis, Stefan C. Grant, Katherine M.W. Pisters, Mark G. Kris, Karen Woolley, Ennapadam Venkatraman, Robert T. Heelan

    Publicado 1995
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  19. 19
    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib

    KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib por William Pao, Theresa Y. Wang, Gregory J. Riely, Vincent A. Miller, Qiulu Pan, Marc Ladanyi, Maureen F. Zakowski, Robert T. Heelan, Mark G. Kris, Harold Varmus

    Publicado 2005
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  20. 20
    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors

    Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors por Jennifer J. Wheler, Johnique T. Atkins, Filip Janků, Stacy L. Moulder, Philip J. Stephens, Roman Yelensky, Vicente Valero, Vincent A. Miller, Razelle Kurzrock, Funda Meric‐Bernstam

    Publicado 2016
    Ligazón do recurso Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: